Cytek Biosciences (CTKB)
(Delayed Data from NSDQ)
$3.64 USD
+0.04 (1.11%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $3.64 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTKB 3.64 +0.04(1.11%)
Will CTKB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CTKB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTKB
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
CTKB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates
Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates
Other News for CTKB
Cytek Biosciences Elects New Directors at Annual Meeting
Analysts Conflicted on These Healthcare Names: Cytek Biosciences (CTKB), Dexcom (DXCM) and Solid Biosciences (SLDB)
CFO Makes Bold Move with Major Stock Purchase in Cytek Biosciences!
Insider Buying: William Mccombe Acquires 35,000 Shares of Cytek Biosciences Inc (CTKB)